Silk Fibroin Nanoparticle Functionalization with Arg-Gly-Asp Cyclopentapeptide Promotes Active Targeting for Tumor Site-Specific Delivery.

RGD active targeting anticancer curcumin silk fibroin nanoparticles

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
09 Mar 2021
Historique:
received: 23 02 2021
accepted: 03 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

Arg-Gly-Asp (RGD)-based cyclopentapeptides (cRGDs) have a high affinity towards integrin αvβ3 and αvβ5, which are overexpressed by many tumor cells. Here, curcumin-loaded silk fibroin nanoparticles (SFNs) have been functionalized on the surface with cRGD to provide active targeting towards tumor cells; a "click reaction" between the RGD-based cyclopentapeptide carrying an azide group and triple-bond-functionalized nanoparticles has been exploited. Both naked and functionalized SFNs were less than 200 nm in diameter and showed a round-shaped morphology but, after functionalization, SFNs increased in size and protein molecular weight. The functionalization of SFNs' surfaces with cRGD provided active internalization by cells overexpressing integrin receptors. At the lowest concentration tested (0.01 mg/mL), functionalized SFNs showed more effective uptake with respect to the naked by tumor cells that overexpress integrin receptors (but not for non-overexpressing ones). In contrast, at higher concentrations, the non-specific cell membrane protein-particle interactions are promoted and coupled to specific and target mediated uptake. Visual observations by fluorescence microscopy suggested that SFNs bind to integrin receptors on the cell surface and are then internalized by endocytosis. Overall, SFN functionalization provided in vitro active targeting for site-specific delivery of anticancer drugs, boosting activity and sparing healthy organs.

Identifiants

pubmed: 33803385
pii: cancers13051185
doi: 10.3390/cancers13051185
pmc: PMC7967211
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Interreg V-A Italy-Switzerland 2014-2020 : ATEx-Advanced Therapies Experiences.
ID : Project ID 637541.

Références

J Org Chem. 2017 Oct 20;82(20):11091-11101
pubmed: 28953382
Biomacromolecules. 2016 Jun 13;17(6):2010-8
pubmed: 27050797
ACS Nano. 2019 Oct 22;13(10):12171-12183
pubmed: 31580642
Int J Oncol. 2018 Dec;53(6):2683-2694
pubmed: 30280197
J Org Chem. 2019 Dec 6;84(23):15726-15734
pubmed: 31693859
ChemMedChem. 2008 Oct;3(10):1589-603
pubmed: 18770516
Cancers (Basel). 2017 Jul 26;9(8):
pubmed: 28933725
Pharmacol Res. 2016 Nov;113(Pt A):55-61
pubmed: 27498157
J Control Release. 2017 Sep 28;262:104-117
pubmed: 28736264
Pharmaceutics. 2019 Jun 17;11(6):
pubmed: 31213025
Cells. 2018 Oct 30;7(11):
pubmed: 30380806
Biotechniques. 2007 Jul;43(1 Suppl):25-30
pubmed: 17936939
Int J Oncol. 2013 Jan;42(1):83-92
pubmed: 23174862
Cells. 2019 Aug 23;8(9):
pubmed: 31450843
J Pharm Biomed Anal. 2020 Jul 15;186:113291
pubmed: 32334133
Chimia (Aarau). 2017 Oct 25;71(10):712-715
pubmed: 29070415
Mini Rev Med Chem. 2009 Oct;9(12):1439-46
pubmed: 19929817
Nat Protoc. 2011 Sep 22;6(10):1612-31
pubmed: 21959241
Int J Mol Sci. 2019 Feb 27;20(5):
pubmed: 30818786
Int J Pharm. 2017 Mar 30;520(1-2):86-97
pubmed: 28163224
Cells. 2019 Nov 13;8(11):
pubmed: 31766310
Nat Methods. 2015 May;12(5):404-6
pubmed: 25775044
Soft Matter. 2018 Jan 24;14(4):546-557
pubmed: 29327746
J Pharm Pharmacol. 2001 Jan;53(1):57-66
pubmed: 11206193
J Control Release. 2010 Dec 1;148(2):135-46
pubmed: 20797419
Colloids Surf B Biointerfaces. 2009 Jul 1;71(2):325-30
pubmed: 19361963
Nanomedicine (Lond). 2019 Mar;14(6):753-765
pubmed: 30741596
Adv Colloid Interface Sci. 2020 May;279:102162
pubmed: 32334131
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Int J Pharm. 2010 Mar 30;388(1-2):242-50
pubmed: 20060449
J Am Chem Soc. 2004 Nov 10;126(44):14350-1
pubmed: 15521743
Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110060
pubmed: 31546370
Int J Nanomedicine. 2016 Nov 10;11:5945-5958
pubmed: 27877040
Eur J Pharm Biopharm. 2019 Apr;137:37-45
pubmed: 30772432
Sci Rep. 2019 Jan 29;9(1):900
pubmed: 30696847
Acta Biomater. 2016 Jan;30:388-396
pubmed: 26621698
Biomaterials. 2018 Apr;161:306-320
pubmed: 29427926
Molecules. 2018 Apr 04;23(4):
pubmed: 29617302
J Clin Oncol. 2020 Apr 1;38(10):1081
pubmed: 32013670
Nat Rev Cancer. 2002 Aug;2(8):563-72
pubmed: 12154349
Acta Pharm Sin B. 2019 Nov;9(6):1145-1162
pubmed: 31867161

Auteurs

Elia Bari (E)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.

Massimo Serra (M)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.

Mayra Paolillo (M)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.

Eric Bernardi (E)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.

Sara Tengattini (S)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.

Filippo Piccinini (F)

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Piero Maroncelli 40, I-47014 Meldola, Italy.

Cristina Lanni (C)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.

Marzio Sorlini (M)

Department of Innovative Technologies, SUPSI, Lugano University Centre, Campus Est, Via la Santa 1, 6962 Viganello, Switzerland.
PharmaExceed Srl, Piazza Castello 19, I-27100 Pavia, Italy.

Giovanni Bisbano (G)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.

Enrica Calleri (E)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.

Maria Luisa Torre (ML)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.
PharmaExceed Srl, Piazza Castello 19, I-27100 Pavia, Italy.

Sara Perteghella (S)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, I-27100 Pavia, Italy.
PharmaExceed Srl, Piazza Castello 19, I-27100 Pavia, Italy.

Classifications MeSH